Eterna Therapeutics Gross Profit

The latest gross profit for ERNA is $-160K as of June 2026. That compares with $360K in the prior-year period — down 143.1% year over year. That is below the Telecommunications sector average of $650B. Investors often review this figure alongside Eterna Therapeutics's historical trend and sector peers before judging valuation or financial health.

Over the past year, ERNA's gross profit moved from $360K to $-160K — a 143.1% year-over-year decrease. If the trend continues in the same direction for several quarters, it can signal a meaningful shift in Eterna Therapeutics's operating scale or balance-sheet position.

Against Telecommunications companies, ERNA currently prints $-160K for gross profit, while the sector average sits near $650B. That is roughly 100.0% below the sector mean. Large gaps often invite a closer look at Eterna Therapeutics's growth, margins, and balance sheet.

A gross profit figure of $-160K for ERNA is a snapshot of scale on that line item. On its own it does not say whether the business is healthy — you also want growth rate, margins, and how the number compares with similar companies. The Telecommunications average is about $650B. Explore the charts below for those layers of context.

After noting ERNA's gross profit ($-160K), review year-over-year change from $360K, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.